-
Latest News
Archives
Tag Archives: Rintatolimod
Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Clinical Trial Arena: AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection, 7 January 2021 AIM ImmunoTech has dosed its first Covid-19 ‘long hauler’ patient in the active AMP-511 Expanded Access Program (EAP) with the Ampligen (rintatolimod) … Continue reading
Posted in News
Tagged ampligen, COVID-19, Dr Charles Lapp, Hunter-Hopkins Center, long Covid, long haulers, post-viral fatigue syndrome, Rintatolimod
Comments Off on Ampligen – AIM doses first ‘long hauler’ patient in trial of post-Covid-19 infection
Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS
Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, by David R Strayer, Diane Young, William M Mitchell in PLoS ONE 15(10): e0240403, Oct 29 2020 [doi.org/10.1371/journal.pone.0240403] Research … Continue reading
Posted in News
Tagged ampligen, David R Strayer, Diane Young, exercise tolerance testing, exercise treadmill tolerance, Intention to treat analysis, Rintatolimod, William M Mitchell
Comments Off on Effect of disease duration in a randomized phase III trial of rintatolimod, an immune modulator for ME/CFS
Endocrine immune regulation in… women with CFS
Leveraging prior knowledge of endocrine immune regulation in the therapeutically relevant phenotyping of women with Chronic Fatigue Syndrome, by Matthew C Morris, Katherine Cooney, Hooman Sedghamiz, Maria Abreu, Fanny Collado, Elizabeth G Balbin, Travis JA Craddock, Nancy G Klimas, Gordon … Continue reading
Posted in News
Tagged Dr Nancy Klimas, Elizabeth G Balbin, endocrine regulation, Fanny Collado, Gordon Broderick, Hooman Sedghamiz, immune regulation, Katherine Cooney, Maria Abreu, Mary Ann Fletcher, Matthew C Morris, numerical modeling, Rintatolimod, rituximab, Travis JA Craddock
Comments Off on Endocrine immune regulation in… women with CFS
Making the Case For Ampligen and ME/CFS
Simmaron research blog post, by Cort Johnson 23 June 2016: Making the Case for Ampligen in Chronic Fatigue Syndrome (ME/CFS) Extracts: Ampligen has been in the FDA pipeline for so many years that it almost seems like a mirage at … Continue reading
Posted in News
Tagged ampligen, Cort Johnson, immunomodulatory drug, Rintatolimod, Simmaron Research
Comments Off on Making the Case For Ampligen and ME/CFS
Efficacy of rintatolimod (Ampligen) in CFS/ME
Review abstract: Chronic fatigue syndrome/ Myalgic encephalomyelitis (CFS/ME) is a poorly understood seriously debilitating disorder in which disabling fatigue is an universal symptom in combination with a variety of variable symptoms. The only drug in advanced clinical development is rintatolimod, … Continue reading
Posted in News
Tagged ampligen, dsRNA, Rintatolimod, TLR3 agonist, Toll-Like Receptor 3 agonist, WM Mitchell
Comments Off on Efficacy of rintatolimod (Ampligen) in CFS/ME
Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)
Research abstract: Background: Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is a debilitating disease of unknown pathogenesis consisting of a variety of flu-like symptoms including severe fatigue. Initial analysis of the use of rintatolimod (Poly I: Poly C12U), a selective TLR3 agonist, … Continue reading
Posted in News
Tagged ampligen, Bruce C Stouch, by David R Strayer, Dr Charles Lapp, Dr Daniel Peterson, Dr David Strayer, Dr Lucinda bateman, exercise intolerance, Karnofsky Performance Score, PolyI:C12U, Quality of life, Responders to Rintatolimod, Rintatolimod, Short form 36, Staci R Stevens
Comments Off on Characteristics of CFS/ME sub-group who respond to Rintatolimod (Ampligen)
